Finanzen von INVO Fertility Inc (IVF)IVFINVO Fertility Inc

INVO Fertility Inc (IVF) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinic revenue, accounting for 99.6% of total sales, equivalent to $2.17M. Another important revenue stream is Domestic product revenue. Understanding this composition is critical for investors evaluating how IVF navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, INVO Fertility Inc maintains a gross margin of 28.37%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -59.28%, while the net margin is 40.85%. These profitability ratios, combined with a Return on Equity (ROE) of -203.65%, provide a clear picture of how effectively IVF converts its operational activities into shareholder value.

In the context of the broader market, IVF competes directly with industry leaders such as OGCP and EDVA. With a market capitalization of $2.42M, it holds a significant position in the sector. When comparing efficiency, IVF's gross margin of 28.37% stands against OGCP's N/A and EDVA's 43.75%. Such benchmarking helps identify whether INVO Fertility Inc is trading at a premium or discount relative to its financial performance.

INVO Fertility has shown a positive trend in revenue growth, reporting $2.18 million in Q2 2026, a 17% increase from the previous year. The company also improved its net income to $888,740 in Q2 2026, a significant recovery from previous losses.